Substance Abuse Treatment Market Research Report – Forecast till 2027

Substance Abuse Treatment Market Research Report: By Abuse Type (Alcohol Dependence, Tobacco & Drug Abuse, Treatment (Alcohol Addiction (Disulfiram, Acamprosate, & others), Nicotine Addiction & Drug Abuse))), End User, - Forecast Till 2027

ID: MRFR/HC/5763-HCR | February 2021 | Region: Global | 90 pages         

Substance Abuse Treatment Market

Substance Abuse Treatment Market is expected to register a CAGR of 8 % and was valued at USD 18.5 Billion.

Segmentation

By Abuse Type Alcohol Dependence Tobacco & Drug Abuse Treatment

Key Players

  • Pfizer Inc.
  • Alkermes Plc
  • GlaxoSmithKline Plc.
  • Purdue Pharma LP
  • Allergan
  • Mylan Laboratories
  • Reckitt Benckiser Pharmaceuticals
  • Teva Pharmaceuticals
  • Forest Laboratories
  • Inc.
  • Accord Healthcare
  • Amphastar Pharmaceuticals
  • Apotex
  • BioCorRx
  • Cipla
  • Glenmark
  • INSYS Therapeutics
  • LFB Group
  • Lupin
  • Opiant Technologies
  • Sanofi Aventis
  • Sanquin
  • Sterinova
  • Sun Pharmaceuticals
  • and others

Drivers

  • Increasing trends of cigarette smoking in teenagers
Speak to Analyst Request a Free Sample

Substance Abuse Treatment Market Scenario


substance abuse treatment market is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 11.6% over the forecast period. 


Substance abuse refers to the harmful use of psychoactive substances, including alcohol and illicit drugs.


Increasing trends of cigarette smoking in teenagers is one of the prominent factors driving the Substance Abuse Treatment market. According to the 2015 study published in the Clinical and Translational Investigation journal, More than 60% of individuals start smoking at the age of 13 and more than 90% individuals start smoking before reaching 20 years. It is also reported that 5.8% of the Mexican population comprises adolescents between 13 and 15 years. Of them, 42.8% tried a cigarette at some point in their life.


Various other factors such as increasing incidence of drug addiction, technological advancement in the diagnostics industry, rising patient awareness about substance abuse treatment and improvement in treatment rates and healthcare infrastructure are also expected to propel the growth of the market.


However, poor treatment compliance in some countries and reluctance of individuals for accessing treatment can hamper the market growth over the forecast period.


Segmentation


The global substance abuse treatment market is segmented based on abuse type, treatment type, end user, and region.


The global market for substance abuse treatment, by abuse type is segmented into alcohol dependence, tobacco/nicotine addiction, and drug abuse. The drug abuse segment is anticipated to hold the largest market share owing to the increasing addiction of opioid.


The market, by treatment type, is segmented into alcohol addiction treatment, tobacco/nicotine addiction treatment, and drug abuse treatment. The alcohol addiction treatment segment is further classified as disulfiram, acamprosate, and naltrexone. The tobacco/nicotine addiction treatment segment is further classified as nicotine replacement treatment, and non-nicotine medication. The nicotine replacement treatment segment includes nicotine patch, nicotine gum, nicotine lozenge, nicotine spray, and nicotine inhaler. The non-nicotine medication segment includes bupropion, and varenicline. The drug abuse treatment segment is further classified as methadone, buprenorphine, and naltrexone.


Based on end user, the market is segmented into outpatient treatment centres, residential treatment centres, and inpatient treatment centres.


In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.


The substance abuse treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European substance abuse treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The substance abuse treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The substance abuse treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Substance Abuse Treatment market Share (%), by Region, 2017



Sources: MRFR Analysis


The Americas dominated the global market for substance abuse treatment owing to presence of major market players and rising awareness about substance abuse treatment within the region. In recent years, various private and government organizations have launched campaigns and seminar to spread awareness about substance abuse. For instance, in February 2017, the Ad Council and Viacom have launched the LISTEN campaign and a new PSA to address America’s substance abuse crisis.


In 2017, it was estimated that Europe stood second in the global substance abuse treatment market. This can be attributed to the rising research and development investments.


Asia Pacific was projected to be the fastest growing region in 2017. Factors such as increasing incidences of tobacco addiction and increasing technological advancements within the region are boosting the regional markets of the Asia Pacific region. According to the information published in the Frontiers in Psychiatry journal, China is facing an immense public health challenge from tobacco smoking. It is estimated that number of deaths, due to cigarette smoking, will reach 2 million by 2030 and 3 million by 2050.


On the other hand, the Middle East and Africa held least share in the global substance abuse treatment market due to the low per capita income, especially within the African region.


Key players


Some of the key players in the global substance abuse treatment market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., Purdue Pharma LP, Allergan, Mylan Laboratories, Reckitt Benckiser Pharmaceuticals, Teva Pharmaceuticals, Forest Laboratories, Inc., Accord Healthcare, Amphastar Pharmaceuticals, Apotex, BioCorRx, Cipla, Glenmark, INSYS Therapeutics, LFB Group, Lupin, Opiant Technologies, Sanofi Aventis, Sanquin, Sterinova, Sun Pharmaceuticals, and others.


Research Methodology


Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analysing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for extensive, technical, market-oriented, and commercial study of the substance abuse treatment. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company web sites, international organization of chemical manufacturers, some paid databases, and many others.


Intended Audience



  • Pharmaceutical Companies

  • Government and Private Laboratories

  • Research and Development (R&D) companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Market Segmentation and Key Market Players


Substance Abuse Treatment Market, by Abuse Type



  • Alcohol Dependence

  • Tobacco/Nicotine Addiction

  • Drug Abuse

  • Others


Substance Abuse Treatment Market, by Treatment Type



  • Alcohol Addiction Treatment

    • Disulfiram

    • Acamprosate

    • Naltrexone



  • Tobacco/Nicotine Addiction Treatment

    • Nicotine Replacement Treatment

      • Nicotine Patch

      • Nicotine Gum

      • Nicotine Lozenge

      • Nicotine Spray

      • Nicotine Inhaler



    • Non-Nicotine Medication

      • Bupropion

      • Varenicline





  • Drug Abuse Treatment

    • Methadone

    • Buprenorphine

    • Naltrexone




Substance Abuse Treatment Market, by End User



  • Outpatient Treatment Centers

  • Residential Treatment Centers

  • Inpatient Treatment Centers



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   11.6% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Abuse type, Treatment type, End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., Purdue Pharma LP, Allergan, Mylan Laboratories, Reckitt Benckiser Pharmaceuticals, Teva Pharmaceuticals, Forest Laboratories, Inc., Accord Healthcare, Amphastar Pharmaceuticals, Apotex, BioCorRx, Cipla, Glenmark, INSYS Therapeutics, LFB Group, Lupin, Opiant Technologies, Sanofi Aventis, Sanquin, Sterinova, Sun Pharmaceuticals, and others
  Key Market Opportunities

  • Increasing incidence of drug addiction
  • Technological advancement in the diagnostics industry
  • Rising patient awareness about substance abuse treatment
  • Improvement in treatment rates and healthcare infrastructure
  •   Key Market Drivers   Increasing trends of cigarette smoking in teenagers


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Substance abuse refers to the harmful use of psychoactive substances, including alcohol and illicit drugs.

    Increasing trends of cigarette smoking in teenagers is one of the prominent factors driving the Substance Abuse Treatment market. Various other factors such as increasing incidence of drug addiction, technological advancement in the diagnostics industry, rising patient awareness about substance abuse treatment and improvement in treatment rates and healthcare infrastructure are also expected to propel the growth of the market.

    Substance Abuse Treatment Market would record a CAGR of 11.6% during the forecast period of 2018 to 2023.

    Substance Abuse Treatment Market would face poor treatment compliances as a major market distraction.

    Americas would dominate the global Substance Abuse Treatment Market.

    Sectors like outpatient treatment centers, residential treatment centers, and inpatient treatment centers are the end users.

    Asia Pacific region would be the fastest-growing in the global Substance Abuse Treatment Market.